

Part of 12th PharmaLab Conference



- Laboratory Optimization, Automation and Digitalization/ Outsourcing in Pharmaceutical Laboratories
- Analytical Instrument Qualification and System Validation



Düsseldorf/Neuss, Germany 25 - 27 November 2024

Highlights

- Outsourcing in Pharmaceutical Laboratories
- Transfer to External Partners
- Technologies that make Lab of the Future
- Digitalisation
- Data Integrity and Cloud Computing
- Data Analysis and Trending for Contamination Control
- Update on USP <1220> and <1058>
- Analytical Procedure Life Cycle
- Opportunities and Challenges from ICH Q2(R2) and Q14

Premium Sponsor 2024: charles river





Background & Objectives

The aim of this conference is to address GMP compliance issues that are currently discussed as hot topics in analytical quality control laboratories and during GMP/FDA inspections.

Due to changing regulatory requirements, pharmaceutical quality control units are continuously facing new challenges. There are many regulatory requirements relevant for pharmaceutical quality control, both in the EU and in the US. Laboratory Managers and Analytical Scientists must be familiar with different GMP-related topics and must be aware of the latest updates and the current interpretation.

This conference therefore deals with the following topics:

- Regulatory and legal requirements
- Analytical challenges
- Data Integrity and CSV
- Machine Learning
- Analytical method validation
- Investigation and prevention of OOS
- Case Studies

Target Audience

This conference will be of significant value to

- Laboratory managers, supervisors and analysts
- Quality control managers
- Heads of quality control
- Qualified Persons (QPs)
- Analytical scientists
- Senior laboratory staff
- Responsible authorities

This conference is also intended for employees in Quality Assurance and from contract laboratories. Furthermore, it is useful for service providers, such as contract research organisations and contract manufacturers.

Moderation

Anna Liznar (Day 1) Dr Karl-Heinz Bauer (Day 2)

Programme

Recent Trend of GMP Observation in Analytical Laboratories Subhrangshu Chaudhury, Centaur Pharmaceuticals

- What inspectors or auditors are looking for?
- Why we should comply with regulatory expectations
- How we can comply with the expectations
- What are the practical challenges
- Way forward

PFAS in Pharmaceutical Products - a View on Findings and Potential Relevance

Stephan Lebertz, SGS Institut Fresenius

- Overview about analytical class of PFAS
- Insight general existing regulation
- Analytical complexity and possibilities
- Occurrence of PFAS in relevant resource materials
- Fist view on findings in pharmaceutical products

Machine Learning in the GMP Lab - Regulation, Validation and Case Studies

Dr Ulrich Köllisch, GxP-CC

- Introduction: Current state of existing commercial ML solutions in the pharmaceutical QC
- Machine Learning Tems and Definitions
- Current regulations such as FDA's discussion paper on AI/ML, EMAs reflection paper and Good Machine Learning Practice
- Validation approaches: Data split, model lifecycle, monitoring and retraining
- Case studies for Risk Management with ML subsystems: CFU counting, Spectroscopy, more to come

Optimizing Precision: Strategies for Validating Analytical Platforms

Dr Mohamad Toutounji, Molgenium

- Introduction to Analytical Platforms
- Standard vs. Accelerated Development
- Method Performance Expectations
- Fit-to-Platform Assessment
- Design Space and Robustness
- Total Analytical Error (TAE)
- Prior Knowledge and Qualifications
- **Regulatory Considerations**

Analytical Method Validation in Pharmaceutical Products according to ICH Q2 and in Biological Matrices according to ICH M10 using HPCL-UV, HPLC-MS and ELISA

Dr Reingard Raml, JOANNEUM RESEARCH Forschungsgesellschaft

- Method Development: Avoiding Future Pitfalls
- Solid Risk analysis and study plan
- System Suitability: A Risk-Based Approach
- Investigations/Deviations during Validation Projects
- Data Integrity during Validation Projects
- Comprehensive Audit Trail Review

Data Integrity and CSV of the Computerised Systems used to Manage GxP data – a Necessary Precondition for a Valid (Bio) Analytical Method?

Dr Timo G. Kretzschmar, TiKrESolution

- The role of "Data", electronic, and computerised systems in the application of ICH M10 Guideline
- Dependence of data from platform/technology important issue
- The integrity and validity of the results within the focus

 some examples
- Data relationship of the validation parameters (like LLOQ, ULOQ, accuracy, precision etc.)
- The role of e.g. LIMS as documentation tool
- Data integrity and eCTD (regarding submission)

Digitalisation and Automation of Validation Activities *Christophe Girardey, wega Informatik*

- The sad reality of today's validation processes
- Challenges in our ever-changing digital world
- Where can digital tools simplify the validation process?
- The regulatory perspective on automated testing
- How can non-IT people create automated tests?
- What are the advantages and disadvantages of automated tests?

Unraveling Out-of-Trend Stability Results: A Case Study in Identification and Investigation Sanja Despotovska, Alkaloid

- Regulatory Basis for OOT Results
- Guidelines for OOT Results
- Definition of Trend
- Definition of OOT Result
- OOT Results During Stability Testing

Concepts to Prevent Lab Errors & Unconfirmed OOS in QC Laboratories

Dr Karl-Heinz Bauer, Boehringer Ingelheim International

- Terms & Definitions
- Regulatory Requirements
- The relevance of the Failure/Error Culture
- Good questions for better answers
- Investigation of Error-Root-Cause

Health Authority Challenges to the Well Established Dissolution Specification of a Mature Drug Product - a Case Study Dr Lukas Sonnenschein, Merck Healthcare

- Description of historic background, evolution of drug product
- Description of recent Health Authoritiy requests related to dissolution
- Summary of given justifications and respective feedback from Health Authorities - dogmatic background
- On-going mitigations to address Health Authority concerns and improve analytical testing

Hard Facts about Softgels: Analytical Challenges and Regulatory Gaps

Dr Ana Petkovska, Patheon by Thermo Fisher Scientific

- Analytical procedures challenges for Soft Gelatin Capsules (SGCs)
- Challenges associated with the different physical forms within the encapsulated materials
- Dissolution challenges inherent to SGCs
- Discussion about the conspicuous absence of specific references to SGCs in International Council for Harmonization (ICH), Federal Drug Administration (FDA) guidelines and European Medical Agency (EMA).

Applying Life Cycle and Validation Principles to the Customized Amplex UltraRed Assay

Dr Alexandra Heussner, Vetter Pharma

- Development and validation of a customized Amplex UltraRed Assay for sensitive hydrogen peroxide detection in pharmaceutical water
- Tool in process development and qualification using water for injection (WfI) in cleanrooms and isolators Overview of the development and validation activities for this analytical procedure in line with the ICH guidelines Q14 and Q2
- Insights into the results and hurdles of such an approach.

GMP Compliance Trends in Analytical Laboratories 26/27 November 2024

Speakers



Subhrangshu Chaudhury Centaur Pharmaceuticals Head of Quality and Vice President



Stephan Lebertz SGS INSTITUT FRESENIUS Operational Laboratory Manager



Dr Ulrich Köllisch GxP-CC Managing Partner



Dr Mohamad Toutounji Molgenium Founder and Managing Director



Dr Reingard Raml

JOANNEUM RESEARCH Forschungsgesellschaft, HEALTH – Institute for Biomedical Research and Technologies Deputy Head of Research Group Bioanalytics and metabolomics



Dr Timo G. Kretzschmar

TiKrESolution - Dr. Timo G. Kretzschmar Business and IT Consultancy Owner, Senior Consultant



Christophe Girardey

wega Informatik Managing Director and Head of CSV & QA



Sanja Despotovska

Alkaloid Associate Manager - Stability, Quality Control, Pharmaceuticals



Dr Karl-Heinz Bauer

Boehringer Ingelheim International Senior Project Portfolio Manager



Dr Lukas Sonnenschein Merck Healthcare Global Analytical Technology Lead Expert



Dr Ana Petkovska Patheon by Thermo Fisher Scientific Research and Development Supervisor



Dr Alexandra Heussner Vetter Pharma Laboratory manager/ Team leader, Analytical Science Laboratory (ASL)



Background & Objectives

Day 1 of this conference will show possibilities to optimize the organization of an analytical laboratory. The optimization of structures and processes in the laboratory will be addressed. Furthermore, the possibilities of automation will be presented, along with the benefits that can result from the optimization of the method portfolio. Modern approaches to cost savings while maintaining GMP compliance will also be presented.

Day 2 will highlight the wide range of regulatory requirements and practical aspects that need to be considered when testing on a contract basis or outsourcing activities. The conference particularly addresses topics that are relevant from a GMP point of view.

The pressure that the pharmaceutical industry is under today to reduce costs and increase efficiency and effectiveness applies equally to analytical laboratories. Often, waiting for the results of quality control is still a speed-limiting step in the entire production process. With this conference, participants will get to know tools for more effective and efficient control of laboratory activities.

There are various reasons for outsourcing analytical testing. Tests are sometimes outsourced only for specific projects. However, the analyses are sometimes conducted externally for each batch of a product in routine quality control, for example, if the manufacturer does not have the necessary know-how or the required capacity.

You will be informed about:

- Optimization of laboratory processes
- Cost-efficient design of a laboratory
- Automation and optimization of environmental monitoring
- Case studies for laboratory automation/digitalization
- New analysis methods for the optimization of processes in the laboratory
- Tools to measure and monitor optimizations
- Practical aspects to consider when outsourcing activities
- Transfer of analytical procedures
- Practical aspects to consider when establishing contracts

Target Audience

This conference will be of significant value to

- Laboratory managers, supervisors and analysts
- Quality control managers
- Heads of quality control
- Qualified Persons (QPs)
- Analytical scientists
- Senior laboratory staff
- Responsible authorities

This conference is also intended for employees in Quality Assurance and from contract laboratories. Furthermore, it is useful for service providers, such as contract research organisations and contract manufacturers.

Moderation

Programme Day 1

Fortifying the Future: Advanced IT Security for Modern Labs Joachim Post, wega Informatik

- Critical IT security aspects in laboratories.
- Informatics systems like LIMS, ELN, SDMS, LES, and CDS
- Importance of flexibility, configurability, and seamless data exchange
- Cybersecurity and measures include securing network gateways, malware prevention, and patch management
- Cloud-based LIMS applications, mobile device support, and intelligent data analysis integration

Potentials of an ERP Managed Logistic System for the Pharmaceutical Laboratory

Julia Abadir, VelaLabs

- Advantages of the inventory-managed purchasing strategy
- KPI and their potential for optimizing the material usage rate, lifecycle of goods, cost efficiency, etc.

Process Mapping and Redesign as the Basis for Laboratory Digitalisation

Dr Bob McDowall, R.D. McDowall Limited

- Understand and apply GMP regulations for electronic working
- Do not automate the status quo: map and redesign your process to work electronically
- Use informatics applications to drive digitalisation
- Case study examples of digitalisation projects

Sub-Visible Particulate Matter Testing – Reduce Variability in Blank Values with Automatization and Optimization – a Practical Case Study on Different Techniques

Dr Melanie Zerulla-Wernitz, Vetter Pharma Fertigung

- Procedure for blank value determination using light obscuration (LO) technique
- Implementation of an automated pipetting system was implemented for micro-flow imaging (MFI)
- Fully automated blank value determination for particlefree containers

Foster Environmental Monitoring Results with Advanced Automated Systems

Laurent Leblanc, bioMérieux

- An overview of the challenges of the EM control
- The evolution of the regulatory context
- How important each elements of a fully automated EM solutions are to guarantee reliable results
- How the introduction of new incubation regimes, such as one media type with one temperature could be an opportunity to speed up the availability of EM data

Dr Karl-Heinz Bauer (Day 1) Johannes Oberdörfer (Day 2)

Laboratory Optimization, Automation and Digitalization/Outsourcing in Pharmaceutical Laboratories | 26/27 November 2024

Automation of Environmental Monitoring Workflow Adele Gisselmann, Merck

- Introduction of automated air sampling in cleanrooms with mobile robot
- Ready-to-use solution for traditional EM for fill and finish in gloveless isolators, improving traceability and safety
- Integration of automated plate reading solution in the EM workflow

Practical Examples of 5s Optimizations in Offices & QC-Labs *Dr Karl-Heinz Bauer, Boehringer Ingelheim International*

- Terms & Definitions
- Meaning & Advantages of 5S / KAIZEN
- Why 5S?
- Description of 5S in detail
- Practical examples and use cases of 5S



Transfer of Analytical Procedures. Practical Handling of Transfers to Different Types of CMO's

Ulla Bondegaard, Novo Nordisk

- Practical differences between internal and external method transfers
- Transfer set up for different types of contract laboratories
- Cultural aspects of the collaboration
- Risk based scaling of the activities to fit the future activities in the receiving laboratory
- Scaling the activities to fit the competences of the receiving laboratory

Construction of a New Hazardous Materials Storage Facility for a Contract Laboratory

Dr Jochen Kolb, BioChem Labor für biologische und chemische Analytik

- Construction of the hazardous materials storage facility
- Legal requirements
- Required permits
- Operation of the hazardous materials storage facility

Lifecycle Management of Analytical Outsourcing Erick Sjöberg, Eurofins

- ICH Q6 and ICH 12
- Practical Lifecycle Management
- Cost-effectiviness in outsourcing QC activities
- Quality agreements pros and cons

Regulatory Considerations for E&L Labs and Methods. From Pharmaceuticals to Medical Devices and in between - Combination Products

Dr Andreas Nixdorf, SGS INSTITUT FRESENIUS

- Regulatory demands for Extractables and Leachables methods and executing labs
- Difference between the product categories
- Pharmaceuticals (<1663>, <1664>), Medical Devices (ISO 10993), Kombinationsprodukte (compromise)
- Focus on chemical analytical part and lab requirements

Speakers



Joachim Post wega Informatik Senior Consultant and Business Analyst



Julia Abadir VelaLabs Head of Equipment Qualification, Procurement and Logistics



Dr Bob McDowall R. D. McDowall Limited Member of the AQCG Board and Member of the ECA IT Compliance Interest Group



Dr Melanie Zerulla-Wernitz Vetter Pharma Fertigung Head of Analytical Science Laboratory



Laurent Leblanc bioMérieux Senior R&D Manager



Adele Gisselmann Merck Global Product Manager



Dr Karl-Heinz Bauer Boehringer Ingelheim International Senior Project Portfolio Manager



Ulla Bondegaard Novo Nordisk A/S, Denmark Specialist



Dr Jochen Kolb BioChem Labor für biologische und chemische Analytik Managing Director



Erick Sjöberg Eurofins, Sweden Head of QA Sweden and Global QA Associate



Dr Andreas Nixdorf SGS INSTITUT FRESENIUS Business Development Manager

Background & Objectives

During this conference track, participants will get an overview of the regulatory requirements for the qualification of analytical equipment and the software validation of computerized systems. Additionally, practical advice on successful approaches to calibration, qualification, validation, and routine monitoring of instrumentation and systems will be provided. Key requirements of the USP General Chapter <1058> will be presented. Furthermore, selected aspects and comments received related to the new ECA Guide for an Integrated Lifecycle Approach to Analytical Instrument Qualification and System Validation will be highlighted and discussed.

Analytical Instrument Qualification (AIQ) and software validation are processes to ensure that analytical instruments or equipment are suitable for their intended use and produce reliable and accurate results. AIQ is critical for ensuring the quality and integrity of analytical data generated by the instrument, which is essential for making informed decisions in research, development, and quality control processes. It helps minimize the risk of errors, ensure compliance with regulatory requirements, and maintain confidence in the accuracy and reliability of analytical results. Requirements and guidance for the pharmaceutical industry are laid down, among others, by the

- EU GMP Guide
- EU GMP Annex 15: Qualification and Validation
- EU GMP Annex 11: Computerised Systems
- US GMP 21 CFR 211
- USP <1058> Analytical Instrument Qualification
- GAMP 5 Guide

Currently, a USP Expert Committee is reviewing and revising USP <1058>, and the proposal is to change the title of the general chapter to Analytical Instrument Qualification and System Validation (AIQSV).

The ECA Analytical Quality Control Group (AQCG) has developed a new Guide for an Integrated Lifecycle Approach to Analytical Instrument Qualification and System Validation. The ECA has decided to publish the Guide widely by allowing users to download the document free of charge. The PDF file is available in the AQCG members' area.

Target Audience

This conference will be of significant value to

- Laboratory managers, supervisors and analysts
- Quality control managers
- Heads of quality control
- Qualified Persons (QPs)
- Analytical scientists
- Senior laboratory staff
- Responsible authorities

Moderation

Dr Christopher Burgess

Data Quality & Data Integrity Lifecycle Overview Dr Christopher Burgess, Chairman ECA AQCG

- Data quality, Data Integrity & Data Governance; Is there a difference?
- Why the 4Qs model is inadequate for most analytical instruments and systems
- An integrated approach; Lifecycle phases and threads
- Who does what; Roles and Responsibilities

Overview of the ECA AQCG Guide to AIQ&SV Dr Bob McDowall, R.D. McDowall Limited

- Definited for the Contract of the second
 - Rationale for the Guide and the development process
 - What's in and what's out of the AIQSV guide
 Importance of the technical appendices:
 - Importance of the technical appendices: - Practical "How To" Examples of Qualification and Validation
 - Acknowledgements

Risk Assessment in AIQ&SV

Dr Christopher Burgess, Chairman ECA AQCG

- Criticality of the User Requirements Specification
- Analytical instruments & systems are not created equal: qualification/validation approaches depend on intended use
- Understanding why a different intended use could define a different USP <1058> Group and sub type for the same make and model of instrument
- Overview of the AIQSV Guide risk assessment process

Application of the AIQSV Approach to a Bioassay Analytical Instrument and Software

Margarita Sabater, Genmab

- Preparation of risk assessment
- Considerations for different system categories
- URS and integrated qualification
- Plan for ongoing performance qualification

Risk-Based Qualification of HPLC Systems Martina Gjorgjevska, Bionika Pharmaceuticals

- Principles of Risk-Based Qualification for HPLC
- Risk Assessment for HPLC Systems
- Live Examples of Risk-Based HPLC Qualification
- Implementation Strategies (Step-by-step guide on integrating risk management into HPLC qualification: Decisionmaking based on risk assessment outcomes)
- Benefits of a Risk-Based Approach
- Challenges and Mitigation
- Emerging trends in HPLC technologies and risk management

Eurachem Guide for The Fitness for Purpose of Analytical Equipment

Dr Ernst Halder, Eurachem

- Background and objectives
- Rationale for the Guide
- Overview of content

Ongoing Monitoring in Analytical Instrument Performance Qualification

Dr Joachim Ermer, Ermer Quality Consulting

- Importance of continual performance monitoring within the analytical lifecycle
- Suitable instrument monitoring parameters
- Tools for ongoing monitoring (run & control charts)
- Reliable performance parameters (long-term averages)
 Crucial interface: Contributions from instrument suppliers

Overview of General Chapter <1220> Analytical Procedure Lifecycle

Dr Christopher Burgess, Chairman ECA AQCG

- Principles of the APL; a Risk based lifecycle approach
- Structure and approaches
- Modular and holistic activities
- Deviation Management & Change Control

Using the Analytical Target Profile (ATP) for Efficient Procedure Lifecycle Management and Enhanced Analytical Platform Adoption

Dr Amanda Guiraldelli Mahr, formerly USP

- Key role of the ATP in determining analytical procedure attributes and performance criteria
- Strategies for establishing ATP performance requirements
- Case studies showcasing how the ATP and an enhanced approach facilitate technology change, post-approval changes and enable the adoption of analytical platform concepts across diverse product classes
- Risk-based approach outlined in ICH Q14 for identifying established conditions and reporting categories for post approval changes

Importance of Change Control and Deviation Management over the Lifecycle

Silviya Dimitrova, TEVA Pharmaceuticals Industries

- How to ensure compliance
- Important aspects to consider

Efficient Analytical Instrument Qualification - Bridging Laboratory Needs and GMP Compliance Dr Nadine Mendl, ten23 health

- URS Significance for standard off the shelve equipment
- Risk-based qualification approach
- Linking CSV and qualification
- PPQ approaches depending on instrument type
- Defining parameters and acceptance criteria

Lifecycle Roles and Responsibilities Patrick Jackson, GSK

- Analytical instrumentation (installation, qualification, maintenance)
- Method Development (ATP, finding local optima, assessing local edges of failure)
- Method verification (traditional validation, robustness, continuous verification)
- Method transfer (traditional versus ruggedness versus equivalence for the assessment of the same method conditions performed in different laboratories)
- Method lifecycle management (continuous verification, equivalence for method replacement)

Comparison of ICH Q2(R2), ICH Q14 & USP <1220> with the Draft General Chapter in the Chinese Pharmacopeia Dr Gerd Jilge, Board Member ECA AQCG

- Comparison of the draft general chapter in the Chinese Pharmacopoeia with ICH Q2(R2), especially on purpose and content
- Applicability of the chapter USP <1220> and ICH Q14 on the draft general chapter in the Chinese Pharmacopoeia
- Which parts of the APLM chapters can be applied?

Consideration of Uncertainty in Evaluation of Accuracy and Precision according to the New ICH Q2(R2) Dr Joachim Ermer, Ermer Quality Consulting

- Precision levels (system precision, repeatability, intermediate precision, reproducibility)
- Statistical evaluation of precisions (confidence intervals, expanded measurement uncertainty)
- Statistical evaluation of accuracy (confidence, prediction, tolerance intervals)
- Implications and challenges for the design of experimental studies (number of replicates, series/runs)

BOOK ONLINE NOW !

PHARMALAB 2024 | 25 & 26/27 NOVEMBER 2024 DÜSSELDORF/NEUSS

www.pharmalab-congress.com/ registration-congress.html or use the QR code on the right.



Speakers



Dr Christopher Burgess

Burgess Analytical Consultancy Limited Qualified Person, USP Council of Experts 2010 to 2025 and Chairman of the AQCG Board



Dr Bob McDowall

R D McDowall Limited Member of the AQCG Board and Member of the ECA IT Compliance Interest Group



Margarita Sabater Genmab A/S Senior CMC Specialist, Analytical / Member of the AQCG Board



Martina Gjorgjevska Bionika Pharmaceuticals Quality Assurance Manager



Ernst Halder Eurachem National Delegate Eurachem-CH



Dr Joachim Ermer Ermer Quality Consulting Member of the AQCG Board



Dr Amanda Guiraldelli Mahr Formerly US Pharmacopeia Scientific Affairs Manager



Silviya Dimitrova

TEVA Pharmaceuticals Industries QP & Director Global Quality Services Bulgaria and Global QTA / Member of the AQCG Board



Dr Nadine Mendl

ten23 health QC Analytics



Patrick Jackson

GSK Investigator in Chemistry, Manufacturing and Controls - Analytical / Member of the AQCG Board



Dr Gerd Jilge Boehringer Ingelheim Pharma Retired Head of a Method Development Laboratory / Member of the AQCG Board



Key Notes: 26/27 November

The Promise and Challenges of In Vitro and In Silico

Models in Drug Development Dr Julia Schüler, Charles River Laboratories


The presentation will highlight important developments in the drug development technology landscape influenced by the concept of 3R and the evolving legal landscape. General characteristics of the different applications, their translational relevance as well as adoption drivers will be discussed. Case studies from oncology drug development will help to elucidate these trends and their impact on future processes.

Trends & Challenges for the Development & Testing of Biotech Drug Products Prof Dr Hanns-Christian Mahler, Chief Enablement Officer (CEO), ten23 health

The Exhibiton

Is your company specialised in products and services for pharma laboratories?

Take advantage of the unique opportunity to exhibit and get in touch with users and decision makers from the fields of analytics, bio analytics, microbiological lab, QA and QC. Moreover, the Social Event will give you the chance to make new contacts with congress delegates and speakers in a more relaxed atmosphere.



Different stand packages are available:

Standard - Package
6sqm Stand
Costs: € 4,580.00 plus VAT

Standard – Package

12sqm Stand

additionally a second person for attending the conferences Costs: € 7,960.00 plus VAT

PREMIUM – Package 12sqm Stand

(only available once)

Like Standard - Package 12sqm, additionally:

- Named as a premium sponsor and logo in all congress-specific print and online media
- Your logo on all name badges and the exhibition plan
- Ice cream station for lunch break at your stand
- Cocktail bar at the social event (incl. 100 cocktails)

Costs: € 13,960.00 plus VAT

All details at: www.pharmalab-congress.com/exhibitor-infos.html



Materials for your Marketing

As an exhibitor you can take advantage of various marketing materials for promoting your presence. These include

- online exhibition banner for your website and as signature in your e-mails.
- an ad in the GMP Journal (subject to extra charges) get directly in touch with your target group

You will find more detailed information on these materials on the Congress website at www.pharmalab-congress.com.

Sponsoring

Moreover, take advantage of the sponsoring opportunities to make Congress delegates aware of your company. In addition to sponsoring coffee breaks or lunches on the 1st and 2nd Congress day there are plenty of other sponsor possibilities. You will find the details on the website.

Do you have any questions with regard to the exhibition? Then please contact: **Ronny Strohwald**, (Organisation Manager), phone: +49 (0) 6221/84 44-51 E-Mail: strohwald@concept-heidelberg.de

The Fees

A one-day ticket/two-day ticket will enable you to visit the congress (26/27 November 2024) either only on day 1 or only on day 2 or on both days. The charges for the one day tickets are \in 690,- plus VAT, for the two days ticket \in 1.380,- plus VAT (Early Bird Discount until 31 August 2024: \in 590 + VAT per day). They include lunch and beverages during the conferences and in breaks as well as the so-cial event on the evening of the first congress day (Due to the special fees for the congress, ECA membership discounts are not applicable). The visit of the pre-conference on 25 November 2024 for \in 590,- + VAT can be combined with the congress. Charges are payable after receipt of invoice.

Social Event

On the evening of the first congress day, on 26 November 2024, all congress delegates and speakers are invited to a "Get together" in the Congress Center. Take advantage of this opportunity for an information exchange and enjoy the laid-back atmosphere and the entertainment programme.

Location

Crowne Plaza Düsseldorf / Neuss Rheinallee 1, 41460 Neuss Phone: +49 (0) 2131 77 - 00 Fax: +49 (0) 2131 77 - 1367 E-mail: emailus@cphotelduesseldorfneuss.com www.crowneplaza.com/neuss

The Organiser

CONCEPT HEIDELBERG – On behalf of the ECA Academy P.O. Box 10 17 64, D-69007 Heidelberg Phone +49 (0) 62 21/84 44-0 | Fax +49 (0) 62 21/84 44 34 E-mail: info@concept-heidelberg.de www.concept-heidelberg.com

The Contacts:

For questions regarding content:

Dr Markus Funk (Operations Director) Phone: +49 (0) 6221/84 44 40, E-mail: funk@concept-heidelberg.de

For questions regarding reservation, hotel, organisation, exhibition etc.:

Ronny Strohwald (Organisation Manager) Phone: +49 (0) 6221/84 44-51 E-mail: strohwald@concept-heidelberg.de



PHARMALAB 2024 | 25 & 26/27 NOVEMBER 2024 | DÜSSELDORF | REGISTRATION

BOOK ONLINE NOW !



At www.pharmalab-congress.com/registration-congress.html or use the QR code on the right.

To avoid incorrect information, please give us the exact address and full name of the participant.



- 25 November 2024: Pre-Conference 590 € plus VAT
- 96+27 November 2024: PharmaLab Congress & Exhibition (day 1 + 2) 1.380 € 1.180 €* plus VAT
- 9 26 November 2024: PharmaLab Congress & Exhibition (day 1 only) 690 €-590 €* plus VAT
- Participation (day 2 only) 690 €-590 €* plus VAT

*Early Bird Discount until 31 August 2024!

Conference Language: The official conference language will be English.

Particularities of the PharmaLab Congress:

With a one-day ticket/two-day ticket for the PharmaLab Conferences (26/27 November 2024) you can attend any conference offered that day/both days. It includes participation in any conference on that day/on both days and the visit of the exhibition. In addition, it comprises lunch and beverages during the conferences and in breaks (on one or both days) as well as the social event on the evening of the first congress day.

Please mark if you would like to attend the Social Event.

To be able to prepare the conference rooms, please choose the conference you are interested in during the online registration process. Please also mark the day you plan on attending the Congress. Please mark only one conference per day.

Please note

There will be no reservations via Concept Heidelberg. Please book your hotel room directly with the reservation form which you will receive together with your confirmation/invoice! Charges are payable after receipt of the invoice. There will not be any print-outs at the Congress. Instead you will receive all presentations prior to the Congress as downloads. presentations of this Course will be available for download and your print-out one week before the conference.

Please note that no printed materials will be handed out on site and that there will not be any opportunity to print the presentations on site. After the event, you will automatically receive your certificate of participation.



Stay informed with the GMP Newsletters from ECA

The ECA offers various free of charge GMP newsletters for which you can subscribe to according to your needs. Go to www.gmp-compliance.org/gmp-newsletter